
    
      The investigators will evaluate response rate, progression free survival (PFS), overall
      survival (OS), and toxicity in elderly patients with primary central nervous system lymphoma
      (PCNSL) after systemic and intrathecal immunochemotherapy with deferred radiotherapy.
    
  